South Korea · Delayed Price · Currency is KRW PharmaResearch Statistics
Total Valuation
PharmaResearch has a market cap or net worth of KRW 3.26 trillion. The enterprise value is 2.89 trillion.
| Market Cap | 3.26T |
| Enterprise Value | 2.89T |
Important Dates
The next confirmed earnings date is Friday, May 8, 2026.
| Earnings Date | May 8, 2026 |
| Ex-Dividend Date | Dec 29, 2025 |
Share Statistics
PharmaResearch has 10.39 million shares outstanding. The number of shares has increased by 12.34% in one year.
| Current Share Class | 10.39M |
| Shares Outstanding | 10.39M |
| Shares Change (YoY) | +12.34% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 34.92% |
| Owned by Institutions (%) | 16.14% |
| Float | 5.58M |
Valuation Ratios
The trailing PE ratio is 20.99 and the forward PE ratio is 16.17. PharmaResearch's PEG ratio is 0.74.
| PE Ratio | 20.99 |
| Forward PE | 16.17 |
| PS Ratio | 6.07 |
| PB Ratio | 4.50 |
| P/TBV Ratio | 4.94 |
| P/FCF Ratio | 21.23 |
| P/OCF Ratio | 17.78 |
| PEG Ratio | 0.74 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 12.84, with an EV/FCF ratio of 18.84.
| EV / Earnings | 17.51 |
| EV / Sales | 5.39 |
| EV / EBITDA | 12.84 |
| EV / EBIT | 13.81 |
| EV / FCF | 18.84 |
Financial Position
The company has a current ratio of 6.92, with a Debt / Equity ratio of 0.29.
| Current Ratio | 6.92 |
| Quick Ratio | 6.07 |
| Debt / Equity | 0.29 |
| Debt / EBITDA | 0.93 |
| Debt / FCF | 1.39 |
| Interest Coverage | 20.43 |
Financial Efficiency
Return on equity (ROE) is 25.99% and return on invested capital (ROIC) is 48.19%.
| Return on Equity (ROE) | 25.99% |
| Return on Assets (ROA) | 13.97% |
| Return on Invested Capital (ROIC) | 48.19% |
| Return on Capital Employed (ROCE) | 22.73% |
| Weighted Average Cost of Capital (WACC) | 7.43% |
| Revenue Per Employee | 1.08B |
| Profits Per Employee | 332.24M |
| Employee Count | 497 |
| Asset Turnover | 0.56 |
| Inventory Turnover | 1.79 |
Taxes
In the past 12 months, PharmaResearch has paid 48.26 billion in taxes.
| Income Tax | 48.26B |
| Effective Tax Rate | 22.29% |
Stock Price Statistics
The stock price has decreased by -19.62% in the last 52 weeks. The beta is 0.62, so PharmaResearch's price volatility has been lower than the market average.
| Beta (5Y) | 0.62 |
| 52-Week Price Change | -19.62% |
| 50-Day Moving Average | 315,700.00 |
| 200-Day Moving Average | 467,370.00 |
| Relative Strength Index (RSI) | 50.10 |
| Average Volume (20 Days) | 68,329 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, PharmaResearch had revenue of KRW 536.29 billion and earned 165.12 billion in profits. Earnings per share was 14,932.75.
| Revenue | 536.29B |
| Gross Profit | 411.22B |
| Operating Income | 212.33B |
| Pretax Income | 216.51B |
| Net Income | 165.12B |
| EBITDA | 228.14B |
| EBIT | 212.33B |
| Earnings Per Share (EPS) | 14,932.75 |
Balance Sheet
The company has 614.37 billion in cash and 213.00 billion in debt, with a net cash position of 401.37 billion or 38,631.82 per share.
| Cash & Cash Equivalents | 614.37B |
| Total Debt | 213.00B |
| Net Cash | 401.37B |
| Net Cash Per Share | 38,631.82 |
| Equity (Book Value) | 724.55B |
| Book Value Per Share | 66,347.89 |
| Working Capital | 649.74B |
Cash Flow
In the last 12 months, operating cash flow was 183.16 billion and capital expenditures -29.73 billion, giving a free cash flow of 153.44 billion.
| Operating Cash Flow | 183.16B |
| Capital Expenditures | -29.73B |
| Depreciation & Amortization | 15.82B |
| Net Borrowing | -3.37B |
| Free Cash Flow | 153.44B |
| FCF Per Share | 14,768.08 |
Margins
Gross margin is 76.68%, with operating and profit margins of 39.59% and 30.79%.
| Gross Margin | 76.68% |
| Operating Margin | 39.59% |
| Pretax Margin | 40.37% |
| Profit Margin | 30.79% |
| EBITDA Margin | 42.54% |
| EBIT Margin | 39.59% |
| FCF Margin | 28.61% |
Dividends & Yields
This stock pays an annual dividend of 3,700.00, which amounts to a dividend yield of 1.15%.
| Dividend Per Share | 3,700.00 |
| Dividend Yield | 1.15% |
| Dividend Growth (YoY) | 236.36% |
| Years of Dividend Growth | 6 |
| Payout Ratio | 7.10% |
| Buyback Yield | -12.34% |
| Shareholder Yield | -11.20% |
| Earnings Yield | 5.07% |
| FCF Yield | 4.71% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
PharmaResearch has an Altman Z-Score of 11.34 and a Piotroski F-Score of 7.
| Altman Z-Score | 11.34 |
| Piotroski F-Score | 7 |